Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VALN Stock Forecast 2025-2026
$5.72
Current Price
$491.84M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VALN Price Targets
+214.7%
To High Target of $18.00
+144.8%
To Median Target of $14.00
+41.6%
To Low Target of $8.10
VALN Price Momentum
-4.7%
1 Week Change
-9.2%
1 Month Change
-20.3%
1 Year Change
+30.9%
Year-to-Date Change
-34.0%
From 52W High of $8.66
+58.0%
From 52W Low of $3.62
📊 TOP ANALYST CALLS
Did VALN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Valneva is one of their latest high-conviction picks.
Latest VALN Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, VALN has a bullish consensus with a median price target of $14.00 (ranging from $8.10 to $18.00). Currently trading at $5.72, the median forecast implies a 144.8% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward White at HC Wainwright & Co., projecting a 214.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VALN Analyst Ratings
2
Buy
1
Hold
0
Sell
VALN Price Target Range
Low
$8.10
Average
$14.00
High
$18.00
Current: $5.72
Latest VALN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VALN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $14.00 |
| Apr 15, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Apr 9, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Mar 24, 2025 | Guggenheim | Dana Flanders | Buy | Maintains | $15.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $17.00 |
| Feb 5, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $18.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Oct 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $20.00 |
| Sep 25, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $23.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Aug 2, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
Valneva SE (VALN) Competitors
The following stocks are similar to Valneva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Valneva SE (VALN) Financial Data
Valneva SE has a market capitalization of $491.84M with a P/E ratio of 72.7x. The company generates $214.19M in trailing twelve-month revenue with a -43.2% profit margin.
Revenue growth is +50.3% quarter-over-quarter, while maintaining an operating margin of -12.1% and return on equity of -44.1%.
Valuation Metrics
Market Cap
$491.84M
Enterprise Value
$1.11B
P/E Ratio
72.7x
PEG Ratio
-10.2x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+50.3%
Gross Margin
+53.2%
Operating Margin
-12.1%
Net Margin
-43.2%
EPS Growth
+50.3%
Financial Health
Cash/Price Ratio
+17.4%
Current Ratio
2.7x
Debt/Equity
120.5x
ROE
-44.1%
ROA
-19.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Valneva SE (VALN) Business Model
About Valneva SE
What They Do
Develops and commercializes vaccines for infectious diseases.
Business Model
Valneva SE generates revenue by developing and selling vaccines that address unmet medical needs, particularly for travel and endemic diseases. The company focuses on innovation within the biotechnology sector, navigating regulatory approvals to bring its products to market effectively.
Additional Information
Valneva has a robust portfolio that includes vaccines like VLA2001 for COVID-19 and is actively working on solutions for diseases such as Lyme disease and chikungunya. Headquartered in France, the company collaborates with governments and health organizations, emphasizing its role in global health and pandemic preparedness.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
713
CEO
Mr. Thomas Lingelbach
Country
France
IPO Year
2021
Website
valneva.comValneva SE (VALN) Latest News & Analysis
Latest News
Quick Summary
The UK medicine regulator has temporarily restricted the use of Valneva's chikungunya vaccine for individuals aged 65 and older as a precaution.
Why It Matters
Restrictions on Valneva's chikungunya vaccine may impact the company's revenue and market perception, affecting stock performance and investor confidence.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Valneva SE reported positive six-month data on antibody persistence and safety for its chikungunya vaccine IXCHIQ® in a Phase 2 trial with 304 children, aiming for a Phase 3 study in Q1 2026.
Why It Matters
Positive clinical trial results for Valneva's chikungunya vaccine enhance its growth potential and marketability, potentially boosting investor confidence and share value ahead of Phase 3 study.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Valneva SE will hold its Combined General Meeting on June 25, 2025, at 2:00 p.m. CEST in Lyon, France. Documentation for the meeting is now available.
Why It Matters
The announcement of Valneva's Combined General Meeting may signal upcoming strategic decisions, financial updates, or shareholder votes that could impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Valneva SE will hold investor meetings and presentations at various conferences in the U.S. and Europe in June 2025, as announced by the company on May 26, 2025.
Why It Matters
Valneva's management meetings at investor conferences may signal plans for growth or new developments, potentially influencing stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
1 month ago
Quick Summary
Valneva SE's chikungunya vaccine IXCHIQ® has been recommended for pause in elderly individuals by the FDA and CDC due to serious adverse events, following similar actions by ACIP and EMA.
Why It Matters
The FDA and CDC's recommendation to pause Valneva's chikungunya vaccine for the elderly raises safety concerns, potentially impacting sales, market perception, and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Valneva SE (NASDAQ:VALN) will hold its Q1 2025 earnings conference call on May 7, 2025, at 9:00 AM ET, featuring key executives and analysts from major firms.
Why It Matters
The upcoming earnings call for Valneva SE will provide insights into the company's financial health and strategic direction, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VALN Stock
What is Valneva SE's (VALN) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Valneva SE (VALN) has a median price target of $14.00. The highest price target is $18.00 and the lowest is $8.10.
Is VALN stock a good investment in 2025?
According to current analyst ratings, VALN has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VALN stock?
Wall Street analysts predict VALN stock could reach $14.00 in the next 12 months. This represents a 144.8% increase from the current price of $5.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Valneva SE's business model?
Valneva SE generates revenue by developing and selling vaccines that address unmet medical needs, particularly for travel and endemic diseases. The company focuses on innovation within the biotechnology sector, navigating regulatory approvals to bring its products to market effectively.
What is the highest forecasted price for VALN Valneva SE?
The highest price target for VALN is $18.00 from Edward White at HC Wainwright & Co., which represents a 214.7% increase from the current price of $5.72.
What is the lowest forecasted price for VALN Valneva SE?
The lowest price target for VALN is $8.10 from at , which represents a 41.6% increase from the current price of $5.72.
What is the overall VALN consensus from analysts for Valneva SE?
The overall analyst consensus for VALN is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are VALN stock price projections?
Stock price projections, including those for Valneva SE, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 1:33 PM UTC